Cargando…

Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures

PURPOSE: New patient reported outcome (PRO) measures are regularly developed to assess various aspects of the patients’ perspective on their disease and treatment. For these instruments to be useful in clinical research, they must undergo a proper psychometric validation, including demonstration of...

Descripción completa

Detalles Bibliográficos
Autores principales: Anthoine, Emmanuelle, Moret, Leïla, Regnault, Antoine, Sébille, Véronique, Hardouin, Jean-Benoit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275948/
https://www.ncbi.nlm.nih.gov/pubmed/25492701
http://dx.doi.org/10.1186/s12955-014-0176-2
_version_ 1782350198918348800
author Anthoine, Emmanuelle
Moret, Leïla
Regnault, Antoine
Sébille, Véronique
Hardouin, Jean-Benoit
author_facet Anthoine, Emmanuelle
Moret, Leïla
Regnault, Antoine
Sébille, Véronique
Hardouin, Jean-Benoit
author_sort Anthoine, Emmanuelle
collection PubMed
description PURPOSE: New patient reported outcome (PRO) measures are regularly developed to assess various aspects of the patients’ perspective on their disease and treatment. For these instruments to be useful in clinical research, they must undergo a proper psychometric validation, including demonstration of cross-sectional and longitudinal measurement properties. This quantitative evaluation requires a study to be conducted on an appropriate sample size. The aim of this research was to list and describe practices in PRO and proxy PRO primary psychometric validation studies, focusing primarily on the practices used to determine sample size. METHODS: A literature review of articles published in PubMed between January 2009 and September 2011 was conducted. Three selection criteria were applied including a search strategy, an article selection strategy, and data extraction. Agreements between authors were assessed, and practices of validation were described. RESULTS: Data were extracted from 114 relevant articles. Within these, sample size determination was low (9.6%, 11/114), and were reported as either an arbitrary minimum sample size (n = 2), a subject to item ratio (n = 4), or the method was not explicitly stated (n = 5). Very few articles (4%, 5/114) compared a posteriori their sample size to a subject to item ratio. Content validity, construct validity, criterion validity and internal consistency were the most frequently measurement properties assessed in the validation studies. Approximately 92% of the articles reported a subject to item ratio greater than or equal to 2, whereas 25% had a ratio greater than or equal to 20. About 90% of articles had a sample size greater than or equal to 100, whereas 7% had a sample size greater than or equal to 1000. CONCLUSIONS: The sample size determination for psychometric validation studies is rarely ever justified a priori. This emphasizes the lack of clear scientifically sound recommendations on this topic. Existing methods to determine the sample size needed to assess the various measurement properties of interest should be made more easily available. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12955-014-0176-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4275948
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42759482014-12-25 Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures Anthoine, Emmanuelle Moret, Leïla Regnault, Antoine Sébille, Véronique Hardouin, Jean-Benoit Health Qual Life Outcomes Review PURPOSE: New patient reported outcome (PRO) measures are regularly developed to assess various aspects of the patients’ perspective on their disease and treatment. For these instruments to be useful in clinical research, they must undergo a proper psychometric validation, including demonstration of cross-sectional and longitudinal measurement properties. This quantitative evaluation requires a study to be conducted on an appropriate sample size. The aim of this research was to list and describe practices in PRO and proxy PRO primary psychometric validation studies, focusing primarily on the practices used to determine sample size. METHODS: A literature review of articles published in PubMed between January 2009 and September 2011 was conducted. Three selection criteria were applied including a search strategy, an article selection strategy, and data extraction. Agreements between authors were assessed, and practices of validation were described. RESULTS: Data were extracted from 114 relevant articles. Within these, sample size determination was low (9.6%, 11/114), and were reported as either an arbitrary minimum sample size (n = 2), a subject to item ratio (n = 4), or the method was not explicitly stated (n = 5). Very few articles (4%, 5/114) compared a posteriori their sample size to a subject to item ratio. Content validity, construct validity, criterion validity and internal consistency were the most frequently measurement properties assessed in the validation studies. Approximately 92% of the articles reported a subject to item ratio greater than or equal to 2, whereas 25% had a ratio greater than or equal to 20. About 90% of articles had a sample size greater than or equal to 100, whereas 7% had a sample size greater than or equal to 1000. CONCLUSIONS: The sample size determination for psychometric validation studies is rarely ever justified a priori. This emphasizes the lack of clear scientifically sound recommendations on this topic. Existing methods to determine the sample size needed to assess the various measurement properties of interest should be made more easily available. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12955-014-0176-2) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-09 /pmc/articles/PMC4275948/ /pubmed/25492701 http://dx.doi.org/10.1186/s12955-014-0176-2 Text en © Anthoine et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Anthoine, Emmanuelle
Moret, Leïla
Regnault, Antoine
Sébille, Véronique
Hardouin, Jean-Benoit
Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures
title Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures
title_full Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures
title_fullStr Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures
title_full_unstemmed Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures
title_short Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures
title_sort sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275948/
https://www.ncbi.nlm.nih.gov/pubmed/25492701
http://dx.doi.org/10.1186/s12955-014-0176-2
work_keys_str_mv AT anthoineemmanuelle samplesizeusedtovalidateascaleareviewofpublicationsonnewlydevelopedpatientreportedoutcomesmeasures
AT moretleila samplesizeusedtovalidateascaleareviewofpublicationsonnewlydevelopedpatientreportedoutcomesmeasures
AT regnaultantoine samplesizeusedtovalidateascaleareviewofpublicationsonnewlydevelopedpatientreportedoutcomesmeasures
AT sebilleveronique samplesizeusedtovalidateascaleareviewofpublicationsonnewlydevelopedpatientreportedoutcomesmeasures
AT hardouinjeanbenoit samplesizeusedtovalidateascaleareviewofpublicationsonnewlydevelopedpatientreportedoutcomesmeasures